- Home
- NZF vs GLPG Comparison
NZF vs GLPG Comparison
Compare NZF & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NZF | GLPG |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | NZF | GLPG |
|---|---|---|
| Price | $12.87 | $33.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 645.5K | 73.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | N/A | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.98 | $22.59 |
| 52 Week High | $13.02 | $37.78 |
Technical Indicators
Market Signals| Indicator | NZF | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 48.34 |
| Support Level | $12.73 | $33.39 |
| Resistance Level | $13.02 | $34.59 |
| Average True Range (ATR) | 0.11 | 0.61 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 75.41 | 28.41 |
Price Performance
Historical ComparisonAbout NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.